Literature DB >> 20030898

European network for health technology assessment, EUnetHTA: planning, development, and implementation of a sustainable European network for health technology assessment.

Finn Børlum Kristensen1, Marjukka Mäkelä, Susanna Allgurin Neikter, Nina Rehnqvist, Lise Lund Håheim, Berit Mørland, Ruairidh Milne, Camilla Palmhøj Nielsen, Reinhard Busse, Sun Hae Lee-Robin, Claudia Wild, Mireia Espallargues, Julia Chamova.   

Abstract

OBJECTIVES: The European network on Health Technology Assessment (EUnetHTA) aimed to produce tangible and practical results to be used in the various phases of health technology assessment and to establish a framework and processes to support this. This article presents the background, objectives, and organization of EUnetHTA, which involved a total of sixty-four partner organizations.
METHODS: Establishing an effective and sustainable structure for a transnational network involved many managerial, policy, and methodological tools, according to the objective of each task or Work Package. Transparency in organization, financial transactions, and decision making was a key principle in the management of the Project as was the commitment to appropriately involve stakeholders.
RESULTS: EUnetHTA activities resulted in a clear management and governance structure, efficient partnership, and transnational cooperation. The Project developed a model for sustainable continuation of the EUnetHTA Collaboration.
CONCLUSIONS: The EUnetHTA Project achieved its goals by producing a suite of practical tools, a strong network, and plans for continuing the work in a sustainable EUnetHTA Collaboration that facilitates and promotes the use of HTA at national and regional levels. Responsiveness to political developments in Europe should be balanced with maintaining a high level of ambition to promote independent, evidence-based information and well-tested tools for best practice based on a strong network of HTA institutions.

Entities:  

Mesh:

Year:  2009        PMID: 20030898     DOI: 10.1017/S0266462309990754

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  16 in total

1.  Potential benefits of using a toolkit developed to aid in the adaptation of HTA reports: a case study considering positron emission tomography (PET) and Hodgkin's disease.

Authors:  Sheila Turner; Neil Adams; Andrew Cook; Alison Price; Ruairidh Milne
Journal:  Health Res Policy Syst       Date:  2010-05-26

2.  Development and Use of Disease-Specific (Reference) Models for Economic Evaluations of Health Technologies: An Overview of Key Issues and Potential Solutions.

Authors:  Gerardus W J Frederix; Hossein Haji Ali Afzali; Erik J Dasbach; Robyn L Ward
Journal:  Pharmacoeconomics       Date:  2015-08       Impact factor: 4.981

Review 3.  The value of anticancer drugs - a regulatory view.

Authors:  Francesco Pignatti; Ulla Wilking; Douwe Postmus; Nils Wilking; Julio Delgado; Jonas Bergh
Journal:  Nat Rev Clin Oncol       Date:  2021-12-06       Impact factor: 66.675

4.  A framework to start the debate on neonatal screening policies in the EU: an Expert Opinion Document.

Authors:  Martina C Cornel; Tessel Rigter; Stephanie S Weinreich; Peter Burgard; Georg F Hoffmann; Martin Lindner; J Gerard Loeber; Kathrin Rupp; Domenica Taruscio; Luciano Vittozzi
Journal:  Eur J Hum Genet       Date:  2013-05-08       Impact factor: 4.246

5.  ICRS Recommendation Document: Patient-Reported Outcome Instruments for Use in Patients with Articular Cartilage Defects.

Authors:  Ewa M Roos; Luella Engelhart; Jonas Ranstam; Allen F Anderson; Jay J Irrgang; Robert G Marx; Yelverton Tegner; Aileen M Davis
Journal:  Cartilage       Date:  2011-04       Impact factor: 4.634

6.  Consensus-based cross-European recommendations for the identification, measurement and valuation of costs in health economic evaluations: a European Delphi study.

Authors:  Lisanne I van Lier; Judith E Bosmans; Hein P J van Hout; Lidwine B Mokkink; Wilbert B van den Hout; G Ardine de Wit; Carmen D Dirksen; Henk L G R Nies; Cees M P M Hertogh; Henriëtte G van der Roest
Journal:  Eur J Health Econ       Date:  2017-12-19

7.  From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.

Authors:  Dimitra Panteli; Helene Eckhardt; Alexandra Nolting; Reinhard Busse; Michael Kulig
Journal:  Health Res Policy Syst       Date:  2015-09-25

Review 8.  Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.

Authors:  Tamás Zelei; Mária J Molnár; Márta Szegedi; Zoltán Kaló
Journal:  Orphanet J Rare Dis       Date:  2016-06-04       Impact factor: 4.123

9.  The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling.

Authors:  George A K van Voorn; Pepijn Vemer; Dominique Hamerlijnck; Isaac Corro Ramos; Geertruida J Teunissen; Maiwenn Al; Talitha L Feenstra
Journal:  Appl Health Econ Health Policy       Date:  2016-04       Impact factor: 2.561

10.  ASSESSMENT OF MAST IN EUROPEAN PATIENT-CENTERED TELEMEDICINE PILOTS.

Authors:  Anne Granstrøm Ekeland; Astrid Grøttland
Journal:  Int J Technol Assess Health Care       Date:  2015-12-18       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.